Pro Medicus Posts 30% Growth, $407 Million in New Contracts

Pro Medicus Ltd (PMCUF) told its FY 2026 earnings call it delivered 30% constant currency growth and signed $407 million in new contracts, while unveiling a new reporting tool it says can disrupt the radiology software market; the PMCUF line last traded at 118.20, down 9.03% on the day.

Pro Medicus Ltd (PMCUF) used its FY 2026 earnings call to put two numbers in front of investors: growth of 30% on a constant currency basis, and $407 million of new contracts signed. It also introduced a reporting tool that management framed as capable of disrupting the market it sells into. The shares did not take the news the way the numbers might suggest. The PMCUF line last traded at 118.20, down 9.03% from the prior close of 129.94, a drop of 11.74 per share on the session.

That gap between a strong report and a sharp fall is the story worth unpacking. It is a familiar pattern for a high-multiple medical imaging software company whose share price has long carried expectations well ahead of its reported revenue base.

What the 30% constant currency figure actually measures

"Constant currency" strips out the effect of exchange rate movements, so growth is measured as if the currency mix had not changed from the prior year. For a company that reports in Australian dollars but earns a large share of its revenue from US hospital systems and academic medical centers, the distinction matters. A weakening or strengthening greenback can add or subtract several points of headline growth in either direction without a single extra scan being read on the software.

Reporting 30% growth on that basis is the cleaner signal: it says the underlying business — the volume of imaging exams flowing through the platform and the contracts that price them — expanded at that rate regardless of what foreign exchange did. What the disclosure in the lead does not break out is how much of that came from newly implemented contracts versus higher exam volumes on existing ones. Those are different quality tiers of growth. Volume growth on installed accounts arrives with almost no incremental cost and drops through to margin; growth from new implementations comes with onboarding work and a lag between signature and revenue recognition.

The $407 million contract number is a pipeline figure, not revenue

The $407 million in new contracts is the number most likely to be misread. Contracts of this kind in imaging software are typically multi-year, minimum-volume arrangements that convert into revenue over the life of the deal rather than in the year they are signed. So $407 million is a measure of committed future work, not a top-line item.

That has two practical consequences. First, it supports visibility: a book of signed, multi-year commitments makes the next several years of revenue easier to forecast than a business selling one-off licenses. Second, it introduces timing risk that has nothing to do with demand. A large contract signed late in the fiscal year contributes almost nothing to that year's revenue, and the market's reaction often depends on whether the implementation schedule lands sooner or later than analysts had penciled in. Investors reading the full call transcript on GuruFocus will want to check exactly where in the calendar those commitments start billing.

Why a reporting tool changes the addressable market

The new reporting tool is the strategic item on the call, and it is worth separating from the financials. Diagnostic imaging software historically splits into two functions: the viewer that lets a radiologist look at the images, and the reporting layer where the radiologist dictates and structures the findings that go back to the referring physician. A company strong in visualization that adds credible reporting stops being a component supplier and starts competing for the whole radiologist workstation.

Commercially, that does three things. It raises the revenue per exam a vendor can charge, because it is selling more of the workflow. It makes displacement harder, since a customer replacing the vendor now has to replace two entangled systems instead of one. And it opens the door to accounts that were never viewer prospects because their imaging viewer decision was already locked in with an incumbent.

It also raises the execution bar. Reporting sits closer to clinical documentation, coding and billing than viewing does, which means deeper integration with electronic health records and more scrutiny from hospital IT and compliance. Management's characterization of the product as market-disrupting is a claim about the competitive landscape, not a booked result. The evidence will be contract wins where reporting was the reason the customer switched.

The multiple is doing the work in the share price

Management's characterization of the product as market-disrupting is a claim about the competitive landscape, not a booked result.

A 9.03% single-session decline against a report of 30% underlying growth tells you something about positioning rather than about the business. Companies valued on the assumption of sustained high-30s or better growth can fall on results that would be celebrated elsewhere, because the price already discounts the good outcome. Any hint of deceleration, a heavier cost line ahead of a new product launch, or an implementation timetable that slips a quarter is enough to reset the shares.

The broader tape gave the move no cover. On the same session the S&P 500 tracker (SPY) closed at $772.67, down 0.47%, the Nasdaq 100 tracker (QQQ) at $729.87, down 0.16%, and the Dow tracker (DIA) at $534.19, down 0.49%. Those are ordinary drifts. The Pro Medicus decline was company-specific, which points to something in the detail of the call rather than to a risk-off day.

What to watch from here

Three things will determine whether the FY 2026 report reads well a year from now.

Conversion cadence on the $407 million. Watch how quickly signed contracts move to go-live and start generating exam-based revenue, and whether any of them are back-end weighted.
Margin behavior through the reporting launch. A new product typically carries development and support cost ahead of revenue. Whether the operating margin holds while that spend runs is the clearest test of the company's much-discussed cost structure.
Competitive proof for the new tool. A disruption claim needs displaced incumbents. Named accounts where reporting drove the decision would validate it; silence on that front for several quarters would not.

None of the above changes the arithmetic of the current print, which is a business compounding at 30% in constant currency with a large book of committed contracts behind it. What it changes is the pace at which that book becomes revenue — and for a stock priced this richly, pace is most of the argument.

Key facts

PMCUF last trade: 118.20, -9.03% (as of Mon, 17 Aug 2026 20:00 GMT close)
Constant currency growth: 30% in FY 2026
New contracts signed: $407 million
Prior close: 129.94, a 11.74 per-share decline

Frequently asked questions

What did Pro Medicus report for FY 2026?

On its FY 2026 earnings call, Pro Medicus reported 30% growth on a constant currency basis and disclosed $407 million in new contracts signed. It also unveiled a new reporting tool that management presented as capable of disrupting the market it competes in. The company described the period as one of record revenue and strategic expansion.

Why did PMCUF shares fall if growth was 30%?

The PMCUF line closed at 118.20, down 9.03% from a prior close of 129.94. A decline alongside strong growth usually reflects positioning rather than deterioration: when a share price already assumes sustained high growth, any sign of deceleration, higher near-term spending or slower contract implementation can trigger selling.

What does constant currency growth mean?

Constant currency growth measures revenue change as if exchange rates had not moved from the prior year. It removes the distortion created when a company earns in one currency and reports in another. For a business with heavy US revenue reporting in Australian dollars, it gives a cleaner read on underlying demand than the headline figure.

Is the $407 million in contracts the same as revenue?

No. Contracts of this type in imaging software are typically multi-year agreements that convert into revenue gradually as systems go live and exam volumes are billed. The $407 million is committed future work, which improves forecasting visibility but does not land in a single year's income statement.

Why does a reporting tool matter for an imaging software company?

Radiology workflow splits broadly between viewing images and writing the diagnostic report. A vendor strong in viewing that adds credible reporting can charge more per exam, becomes harder to displace because two systems are entangled, and can reach accounts whose viewer decision was already made with a competitor.

How did the broader market perform the same day?

Major index trackers closed modestly lower on Mon, 17 Aug 2026. The S&P 500 tracker SPY ended at $772.67, down 0.47%; the Nasdaq 100 tracker QQQ at $729.87, down 0.16%; and the Dow tracker DIA at $534.19, down 0.49%. Those small moves suggest the Pro Medicus decline was company-specific.

Sources

Pro Medicus Ltd (PMCUF) (FY 2026) Earnings Call Highlights: Record Revenue and Strategic ... — GuruFocus

Photo: Anna Shvets · Pexels Licence — source